In conversation with... Arndt Vogel episode artwork

EPISODE · Jul 31, 2024 · 18 MIN

In conversation with... Arndt Vogel

from Listen to The Lancet Gastroenterology & Hepatology · host The Lancet

Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies.

NOW PLAYING

In conversation with... Arndt Vogel

0:00 18:31

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Gastroenterology & Hepatology?

This episode is 18 minutes long.

When was this Listen to The Lancet Gastroenterology & Hepatology episode published?

This episode was published on July 31, 2024.

What is this episode about?

Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies.

Can I download this Listen to The Lancet Gastroenterology & Hepatology episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!